董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Ryan Rhodes | 男 | Chief Executive Officer and Director | 64 | 174.07万美元 | 160.00 | 2026-06-26 |
| David Horn | 男 | Independent Director | 59 | 未披露 | 未持股 | 2026-06-26 |
| Fran Schulz | 女 | Independent Director | 62 | 6.11万美元 | 0.51 | 2026-06-26 |
| Josh Levine | 男 | Independent Director | 65 | 4.04万美元 | 2.50 | 2026-06-26 |
| Lance Willsey | 男 | Chairman of the Board and Independent Director | 64 | 29.05万美元 | 135.07 | 2026-06-26 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Francois Dietsch | 男 | Chief Accounting Officer | 50 | 未披露 | 5.41 | 2026-06-26 |
| Ryan Rhodes | 男 | Chief Executive Officer and Director | 64 | 174.07万美元 | 160.00 | 2026-06-26 |
| Steven Annen | 男 | Executive Vice President of Marketing and Product Management | 62 | 69.87万美元 | 15.26 | 2026-06-26 |
| Kenneth S. Mobeck | 男 | Chief Financial Officer | 55 | 100.67万美元 | 未持股 | 2026-06-26 |
| Sanket Shah | 男 | General Counsel & Corporate Secretary | 43 | 未披露 | 2.78 | 2026-06-26 |
董事简历
中英对照 | 中文 | 英文- Ryan Rhodes
-
Ryan Rhodes自2016年7月起担任我们的总裁兼首席执行官，自2016年7月起担任我们的董事会成员。Rhodes从2002年1月到2015年6月担任Intuitive Surgical Inc.（手术机器人市场领导者）多个职位，包括全球临床营销副总裁、全球营销高级主管和营销主管。在加入Intuitive Surgical Inc.之前，罗兹先生在强生公司公司Ethicon Inc.担任了11年多的销售、市场营销、专业教育和市场开发等多个管理职位。Rhodes先生拥有圣地亚哥州立大学（San Diego State University）公共管理学士学位。
Ryan Rhodes was appointed as Chief Executive Officer of the Company in May 2023 and as a member of the Board of Directors in August 2023. He has also served as Chief Executive Officer of EDAP's U.S. subsidiary since June 2021. Mr. Rhodes has over 30 years of leadership experience in market development in the medical device industry, including 20 years dedicated to medical robotics. Prior to joining EDAP, Mr. Rhodes served as the Chief Executive Officer of Restoration Robotics, a global leader in robotic aesthetic medicine, where he led the company to a successful merger with Venus Concept Inc. in 2019. Prior to Restoration Robotics, Mr. Rhodes spent over 13 years at Intuitive Surgical, the global leader in medical robotics, where he was a key architect of the company's multi procedure market focus and development efforts, including the successful launch of the global Urology franchise. Prior to Intuitive Surgical, he spent over 11 years in various management positions in sales, marketing, professional education, and market development at Ethicon Inc., a Johnson & Johnson company. Mr. Rhodes holds a B.A. in Public Administration from San Diego State University. - Ryan Rhodes自2016年7月起担任我们的总裁兼首席执行官，自2016年7月起担任我们的董事会成员。Rhodes从2002年1月到2015年6月担任Intuitive Surgical Inc.（手术机器人市场领导者）多个职位，包括全球临床营销副总裁、全球营销高级主管和营销主管。在加入Intuitive Surgical Inc.之前，罗兹先生在强生公司公司Ethicon Inc.担任了11年多的销售、市场营销、专业教育和市场开发等多个管理职位。Rhodes先生拥有圣地亚哥州立大学（San Diego State University）公共管理学士学位。
- Ryan Rhodes was appointed as Chief Executive Officer of the Company in May 2023 and as a member of the Board of Directors in August 2023. He has also served as Chief Executive Officer of EDAP's U.S. subsidiary since June 2021. Mr. Rhodes has over 30 years of leadership experience in market development in the medical device industry, including 20 years dedicated to medical robotics. Prior to joining EDAP, Mr. Rhodes served as the Chief Executive Officer of Restoration Robotics, a global leader in robotic aesthetic medicine, where he led the company to a successful merger with Venus Concept Inc. in 2019. Prior to Restoration Robotics, Mr. Rhodes spent over 13 years at Intuitive Surgical, the global leader in medical robotics, where he was a key architect of the company's multi procedure market focus and development efforts, including the successful launch of the global Urology franchise. Prior to Intuitive Surgical, he spent over 11 years in various management positions in sales, marketing, professional education, and market development at Ethicon Inc., a Johnson & Johnson company. Mr. Rhodes holds a B.A. in Public Administration from San Diego State University.
- David Horn
-
David Horn自2020年5月起担任公司首席财务官。在加入我们之前，Horn先生于2007年5月至2020年5月在投资银行和金融服务公司摩根士丹利任职，在投资银行部内担任Global Healthcare Group的董事总经理。从2003年5月到2007年5月，Horn先生担任Montgomery & Co.，LLC的负责人，该公司是一家并购和私募服务提供商。他拥有普林斯顿大学政治学学士学位和斯坦福大学商学院工商管理硕士学位。
David Horn has served as the company's Chief Financial Officer since May 2020. Prior to joining us, Mr. Horn was with Morgan Stanley, an investment bank and financial services company, from May 2007 to May 2020 where he served as a Managing Director in the Global Healthcare Group within the Investment Banking Department. From May 2003 to May 2007 Mr. Horn served as a Principal at Montgomery & Co., LLC, a provider of merger and acquisition and private placement services. He holds an A.B. in Politics from Princeton University and an M.B.A. from Stanford University Graduate School of Business. - David Horn自2020年5月起担任公司首席财务官。在加入我们之前，Horn先生于2007年5月至2020年5月在投资银行和金融服务公司摩根士丹利任职，在投资银行部内担任Global Healthcare Group的董事总经理。从2003年5月到2007年5月，Horn先生担任Montgomery & Co.，LLC的负责人，该公司是一家并购和私募服务提供商。他拥有普林斯顿大学政治学学士学位和斯坦福大学商学院工商管理硕士学位。
- David Horn has served as the company's Chief Financial Officer since May 2020. Prior to joining us, Mr. Horn was with Morgan Stanley, an investment bank and financial services company, from May 2007 to May 2020 where he served as a Managing Director in the Global Healthcare Group within the Investment Banking Department. From May 2003 to May 2007 Mr. Horn served as a Principal at Montgomery & Co., LLC, a provider of merger and acquisition and private placement services. He holds an A.B. in Politics from Princeton University and an M.B.A. from Stanford University Graduate School of Business.
- Fran Schulz
-
Fran Schulz，于2024年6月加入董事会。朔尔茨女士是一位经验丰富的高管，在安永拥有超过35年的经验，她的职业生涯曾在生命科学行业的大型上市公司和新兴私营公司工作。Schulz女士在处理美国SEC和国际财务报告准则（“IFRS”）事项方面也有丰富的经验。根据SEC、NYSE和NASDAQ的规定，她有资格担任金融专家。Schulz女士目前还担任Senti Biosciences和Menlo College的董事会成员。此前，她曾担任美国国家生物妇女委员会（2013 – 2023）和加州生命科学行业协会的董事会成员。Schulz女士是一名在加利福尼亚州获得许可的持牌注册会计师（CPA）。Schulz女士在门洛学院获得工商管理学士学位。
Fran Schulz joined the Board of Directors in June 2024. Ms. Schulz is a seasoned executive with over 35 years of experience with EY who has spent her career working with large public and emerging private companies in the life sciences industry. Ms. Schulz also has significant experience working on U.S. SEC and International Financial Reporting Standards matters. Ms. Schulz currently also serves as a Board Member of Senti Biosciences and Menlo College. Previously, she served as a Board Member for the National Board of Women in Bio (2013 to 2023) and for the California Life Sciences Industry Association. Ms. Schulz is a licensed certified public accountant (CPA) in California and received her B.S. in Business Administration from Menlo College. - Fran Schulz，于2024年6月加入董事会。朔尔茨女士是一位经验丰富的高管，在安永拥有超过35年的经验，她的职业生涯曾在生命科学行业的大型上市公司和新兴私营公司工作。Schulz女士在处理美国SEC和国际财务报告准则（“IFRS”）事项方面也有丰富的经验。根据SEC、NYSE和NASDAQ的规定，她有资格担任金融专家。Schulz女士目前还担任Senti Biosciences和Menlo College的董事会成员。此前，她曾担任美国国家生物妇女委员会（2013 – 2023）和加州生命科学行业协会的董事会成员。Schulz女士是一名在加利福尼亚州获得许可的持牌注册会计师（CPA）。Schulz女士在门洛学院获得工商管理学士学位。
- Fran Schulz joined the Board of Directors in June 2024. Ms. Schulz is a seasoned executive with over 35 years of experience with EY who has spent her career working with large public and emerging private companies in the life sciences industry. Ms. Schulz also has significant experience working on U.S. SEC and International Financial Reporting Standards matters. Ms. Schulz currently also serves as a Board Member of Senti Biosciences and Menlo College. Previously, she served as a Board Member for the National Board of Women in Bio (2013 to 2023) and for the California Life Sciences Industry Association. Ms. Schulz is a licensed certified public accountant (CPA) in California and received her B.S. in Business Administration from Menlo College.
- Josh Levine
-
Josh Levine，于2024年12月加入董事会。2012年至2022年，Levine先生担任Accuray Incorporated总裁、首席执行官、董事。在担任准确职务的同时，Levine先生于2018-2022年期间担任独立董事，随后于2022-2023年期间担任纳图斯医疗董事会非执行主席。在此之前，Levine先生于2011年担任依免可药物公司总裁、首席执行官和董事会成员。从2004年到2010年，Levine先生担任Mentor Corporation的总裁、首席执行官和董事会成员，通过执行战略转型，他在公司重新定位方面发挥了重要作用。Levine先生在加州大学洛杉矶分校安德森商学院、斯坦福大学和宾夕法尼亚大学完成了高管管理课程，并在亚利桑那大学获得了传播学学士学位。
Josh Levine joined the Board of Directors in December 2024. From 2012 to 2022, Mr. Levine served as President, Chief Executive Officer, and Director of Accuray Incorporated. Cncurrent with his Accuray roles, Mr. Levine served as an independent director from 2018 to 2022 and later as Non Executive Chairman of the board of Natus Medical from 2022 to 2023. Prior to that, Mr. Levine served as President, Chief Executive Officer, and Board Member of Immucor, Inc. in 2011. From 2004 to 2010, Mr. Levine served as President, Chief Executive Officer and Board Member of Mentor Corporation, where he played an instrumental role in repositioning the company through a strategic transformation. Mr. Levine has completed executive management programs at UCLA Anderson School of Business, Stanford University, and the University of Pennsylvania, and received his bachelor's degree in communications from the University of Arizona. - Josh Levine，于2024年12月加入董事会。2012年至2022年，Levine先生担任Accuray Incorporated总裁、首席执行官、董事。在担任准确职务的同时，Levine先生于2018-2022年期间担任独立董事，随后于2022-2023年期间担任纳图斯医疗董事会非执行主席。在此之前，Levine先生于2011年担任依免可药物公司总裁、首席执行官和董事会成员。从2004年到2010年，Levine先生担任Mentor Corporation的总裁、首席执行官和董事会成员，通过执行战略转型，他在公司重新定位方面发挥了重要作用。Levine先生在加州大学洛杉矶分校安德森商学院、斯坦福大学和宾夕法尼亚大学完成了高管管理课程，并在亚利桑那大学获得了传播学学士学位。
- Josh Levine joined the Board of Directors in December 2024. From 2012 to 2022, Mr. Levine served as President, Chief Executive Officer, and Director of Accuray Incorporated. Cncurrent with his Accuray roles, Mr. Levine served as an independent director from 2018 to 2022 and later as Non Executive Chairman of the board of Natus Medical from 2022 to 2023. Prior to that, Mr. Levine served as President, Chief Executive Officer, and Board Member of Immucor, Inc. in 2011. From 2004 to 2010, Mr. Levine served as President, Chief Executive Officer and Board Member of Mentor Corporation, where he played an instrumental role in repositioning the company through a strategic transformation. Mr. Levine has completed executive management programs at UCLA Anderson School of Business, Stanford University, and the University of Pennsylvania, and received his bachelor's degree in communications from the University of Arizona.
- Lance Willsey
-
Lance Willsey，1997年4月以来他一直是董事。从1998年7月到2002年3月，他是DCF资本公司创始合伙人，一家避险基金公司专注于生命科学投资，目前是肿瘤学领域机构投资者的顾问。他自2000年以来一直在哈佛大学（Harvard University）医学院的达纳法伯癌症研究所Genitourinary Oncology 部门的访问委员会任职。他从1997年7月到1998年7月是达纳法伯癌症研究所Genitourinary Oncology 部门的员工。他从1996年7月到1997年7月就职于哈佛大学（Harvard University）医学院麻省综合医院泌尿外科部门，从1992年7月到1996年7月他是一名泌尿外科住院医师。他从2000年到2010年担任Exact Sciences Corporation的董事会成员，一家上市的生物技术公司。他持有密歇根州立大学（Michigan State University）生理学学士学位和韦恩州立大学（Wayne State University）生物学和医学硕士学位。
Lance Willsey joined the Board of Directors in December 2023 and was appointed Chairman of the Board of Directors in September 2024. Dr. Willsey is a urologist who has 36 years of private and public board experience focused in the area of cancer diagnostics and therapeutics. He completed his surgical and urology training at the Massachusetts General Hospital and additional postgraduate training in the Steele Lab, Harvard University and the Dana Farber Cancer Institute. Dr. Willsey is a founding Partner of the healthcare fund DCF Capital. He also served as a director of Exact Sciences from 1999 to 2009 and of Exelixis from 1997 to 2023, and has extensive experience in corporate governance, having served on audit, compensation, finance and scientific advisory committees. Dr. Willsey holds an M.S. and M.D. from Wayne State University. - Lance Willsey，1997年4月以来他一直是董事。从1998年7月到2002年3月，他是DCF资本公司创始合伙人，一家避险基金公司专注于生命科学投资，目前是肿瘤学领域机构投资者的顾问。他自2000年以来一直在哈佛大学（Harvard University）医学院的达纳法伯癌症研究所Genitourinary Oncology 部门的访问委员会任职。他从1997年7月到1998年7月是达纳法伯癌症研究所Genitourinary Oncology 部门的员工。他从1996年7月到1997年7月就职于哈佛大学（Harvard University）医学院麻省综合医院泌尿外科部门，从1992年7月到1996年7月他是一名泌尿外科住院医师。他从2000年到2010年担任Exact Sciences Corporation的董事会成员，一家上市的生物技术公司。他持有密歇根州立大学（Michigan State University）生理学学士学位和韦恩州立大学（Wayne State University）生物学和医学硕士学位。
- Lance Willsey joined the Board of Directors in December 2023 and was appointed Chairman of the Board of Directors in September 2024. Dr. Willsey is a urologist who has 36 years of private and public board experience focused in the area of cancer diagnostics and therapeutics. He completed his surgical and urology training at the Massachusetts General Hospital and additional postgraduate training in the Steele Lab, Harvard University and the Dana Farber Cancer Institute. Dr. Willsey is a founding Partner of the healthcare fund DCF Capital. He also served as a director of Exact Sciences from 1999 to 2009 and of Exelixis from 1997 to 2023, and has extensive experience in corporate governance, having served on audit, compensation, finance and scientific advisory committees. Dr. Willsey holds an M.S. and M.D. from Wayne State University.
高管简历
中英对照 | 中文 | 英文- Francois Dietsch
Francois Dietsch，他于2005年加入EDAP公司，担任内部审计和整合经理，并领导Sarbanes-Oxley法案、公司的子公司的合并财务报表、美国公认会计准则下的财务报表制作的内部控制的实现，其中包括EDAP公司的20F年报。他于2012年被提拔为EDAP公司的法国子公司的现任职务，即集团财务控制经理、财务经理。此前，他曾管理子公司层面的会计公司，主要联络该公司及其外部审计师。他也管理EDAP France公司的财务部门。加入EDAP公司之前，他曾担任Valeo公司（汽车行业的组件和系统的领先全球供应商）的财务职务。他持有University of Paris Dauphine的管理和公司金融硕士学位。
Francois Dietsch Accounting Officer in January 2024. Prior to that position, Mr. Dietsch held the position of Chief Financial Officer of the Company since July 2015. Mr. Dietsch joined EDAP in 2005 as Internal Audit and Consolidation Manager and in 2012 was promoted to Group Financial Control Manager and Finance Manager of EDAP's French subsidiary. Prior to joining EDAP, he held finance positions at Valeo, a leading global supplier of components and systems to the automotive industry. He holds master's degrees in Management and Corporate Finance from the University of Paris Dauphine.- Francois Dietsch，他于2005年加入EDAP公司，担任内部审计和整合经理，并领导Sarbanes-Oxley法案、公司的子公司的合并财务报表、美国公认会计准则下的财务报表制作的内部控制的实现，其中包括EDAP公司的20F年报。他于2012年被提拔为EDAP公司的法国子公司的现任职务，即集团财务控制经理、财务经理。此前，他曾管理子公司层面的会计公司，主要联络该公司及其外部审计师。他也管理EDAP France公司的财务部门。加入EDAP公司之前，他曾担任Valeo公司（汽车行业的组件和系统的领先全球供应商）的财务职务。他持有University of Paris Dauphine的管理和公司金融硕士学位。
- Francois Dietsch Accounting Officer in January 2024. Prior to that position, Mr. Dietsch held the position of Chief Financial Officer of the Company since July 2015. Mr. Dietsch joined EDAP in 2005 as Internal Audit and Consolidation Manager and in 2012 was promoted to Group Financial Control Manager and Finance Manager of EDAP's French subsidiary. Prior to joining EDAP, he held finance positions at Valeo, a leading global supplier of components and systems to the automotive industry. He holds master's degrees in Management and Corporate Finance from the University of Paris Dauphine.
- Ryan Rhodes
Ryan Rhodes自2016年7月起担任我们的总裁兼首席执行官，自2016年7月起担任我们的董事会成员。Rhodes从2002年1月到2015年6月担任Intuitive Surgical Inc.（手术机器人市场领导者）多个职位，包括全球临床营销副总裁、全球营销高级主管和营销主管。在加入Intuitive Surgical Inc.之前，罗兹先生在强生公司公司Ethicon Inc.担任了11年多的销售、市场营销、专业教育和市场开发等多个管理职位。Rhodes先生拥有圣地亚哥州立大学（San Diego State University）公共管理学士学位。
Ryan Rhodes was appointed as Chief Executive Officer of the Company in May 2023 and as a member of the Board of Directors in August 2023. He has also served as Chief Executive Officer of EDAP's U.S. subsidiary since June 2021. Mr. Rhodes has over 30 years of leadership experience in market development in the medical device industry, including 20 years dedicated to medical robotics. Prior to joining EDAP, Mr. Rhodes served as the Chief Executive Officer of Restoration Robotics, a global leader in robotic aesthetic medicine, where he led the company to a successful merger with Venus Concept Inc. in 2019. Prior to Restoration Robotics, Mr. Rhodes spent over 13 years at Intuitive Surgical, the global leader in medical robotics, where he was a key architect of the company's multi procedure market focus and development efforts, including the successful launch of the global Urology franchise. Prior to Intuitive Surgical, he spent over 11 years in various management positions in sales, marketing, professional education, and market development at Ethicon Inc., a Johnson & Johnson company. Mr. Rhodes holds a B.A. in Public Administration from San Diego State University.- Ryan Rhodes自2016年7月起担任我们的总裁兼首席执行官，自2016年7月起担任我们的董事会成员。Rhodes从2002年1月到2015年6月担任Intuitive Surgical Inc.（手术机器人市场领导者）多个职位，包括全球临床营销副总裁、全球营销高级主管和营销主管。在加入Intuitive Surgical Inc.之前，罗兹先生在强生公司公司Ethicon Inc.担任了11年多的销售、市场营销、专业教育和市场开发等多个管理职位。Rhodes先生拥有圣地亚哥州立大学（San Diego State University）公共管理学士学位。
- Ryan Rhodes was appointed as Chief Executive Officer of the Company in May 2023 and as a member of the Board of Directors in August 2023. He has also served as Chief Executive Officer of EDAP's U.S. subsidiary since June 2021. Mr. Rhodes has over 30 years of leadership experience in market development in the medical device industry, including 20 years dedicated to medical robotics. Prior to joining EDAP, Mr. Rhodes served as the Chief Executive Officer of Restoration Robotics, a global leader in robotic aesthetic medicine, where he led the company to a successful merger with Venus Concept Inc. in 2019. Prior to Restoration Robotics, Mr. Rhodes spent over 13 years at Intuitive Surgical, the global leader in medical robotics, where he was a key architect of the company's multi procedure market focus and development efforts, including the successful launch of the global Urology franchise. Prior to Intuitive Surgical, he spent over 11 years in various management positions in sales, marketing, professional education, and market development at Ethicon Inc., a Johnson & Johnson company. Mr. Rhodes holds a B.A. in Public Administration from San Diego State University.
- Steven Annen
Steven Annen自2016年4月起担任我们的产品管理和战略Vice President。他于2015年11月加入公司，担任高级董事，负责产品管理和战略。Annen从2014年1月到2015年10月担任Grabit，Inc.（一家材料处理技术供应商）营销Vice President。Annen从2005年10月到2014年1月担任Intuitive Surgical Inc.（一家机器人手术系统上市制造商）产品营销主管。任职Intuitive Surgical公司之前，Annen先生曾担任公共部门公司的领导职务，包括Veeco Instruments，Inc.（流程设备技术的公开交易供应商）和Adept Technology Inc.（智能视觉引导机器人系统和服务的公开交易供应商）。Annen先生在罗格斯大学（Rutgers University）获得机械工程学士学位，并在麦迪逊威斯康星大学（University of Wisconsin，Madison）获得机械工程硕士学位。
Steven Annen was appointed as the Company's Executive Vice President of Marketing and Product Management in December 2025. Prior to that position, Mr. Annen held the position of Senior Vice President of Marketing and Product Management of the Company since August 2023. Mr. Annen has over 30 years of experience in surgical robotics and instruments, radiation therapy, and image guided industrial robotic systems. Prior to joining EDAP, Mr. Annen served as Senior Vice President of Global Marketing and Product Management at ViewRay, a leading provider of MR guided radiation therapy for four years, and as Vice President of Product Management and Strategy at Invuity, a provider of surgical instruments for breast cancer surgery. Prior to these roles, Mr. Annen led the product marketing function at Intuitive Surgical and held positions of increasing levels of responsibility in marketing and strategy at Grabit, Veeco Instruments and Adept Technology. Mr. Annen holds a Master's degree in Mechanical Engineering from the University of Wisconsin Madison and a Bachelor's degree in Mechanical Engineering from Rutgers University.- Steven Annen自2016年4月起担任我们的产品管理和战略Vice President。他于2015年11月加入公司，担任高级董事，负责产品管理和战略。Annen从2014年1月到2015年10月担任Grabit，Inc.（一家材料处理技术供应商）营销Vice President。Annen从2005年10月到2014年1月担任Intuitive Surgical Inc.（一家机器人手术系统上市制造商）产品营销主管。任职Intuitive Surgical公司之前，Annen先生曾担任公共部门公司的领导职务，包括Veeco Instruments，Inc.（流程设备技术的公开交易供应商）和Adept Technology Inc.（智能视觉引导机器人系统和服务的公开交易供应商）。Annen先生在罗格斯大学（Rutgers University）获得机械工程学士学位，并在麦迪逊威斯康星大学（University of Wisconsin，Madison）获得机械工程硕士学位。
- Steven Annen was appointed as the Company's Executive Vice President of Marketing and Product Management in December 2025. Prior to that position, Mr. Annen held the position of Senior Vice President of Marketing and Product Management of the Company since August 2023. Mr. Annen has over 30 years of experience in surgical robotics and instruments, radiation therapy, and image guided industrial robotic systems. Prior to joining EDAP, Mr. Annen served as Senior Vice President of Global Marketing and Product Management at ViewRay, a leading provider of MR guided radiation therapy for four years, and as Vice President of Product Management and Strategy at Invuity, a provider of surgical instruments for breast cancer surgery. Prior to these roles, Mr. Annen led the product marketing function at Intuitive Surgical and held positions of increasing levels of responsibility in marketing and strategy at Grabit, Veeco Instruments and Adept Technology. Mr. Annen holds a Master's degree in Mechanical Engineering from the University of Wisconsin Madison and a Bachelor's degree in Mechanical Engineering from Rutgers University.
- Kenneth S. Mobeck
Kenneth Mobeck于2024年1月被任命为公司首席财务官。在担任该职位之前，他自2022年12月加入公司以来一直担任EDAP美国子公司的首席财务官一职。Mobeck先生是一位经验丰富的企业和运营财务主管，在医疗技术和领导财务和行政职能的技术组织方面拥有丰富的经验。在加入EDAP之前，Mobeck先生曾在全球领先的放射治疗公司医疗设备制造商Accuray Inc.担任财务和投资者关系副总裁。在任职期间，他负责推动与改善公司经营业绩和战略增长目标相关的几项关键举措。在加入Accuray之前，他曾在Lumentum、Silicon Graphics、惠普企业、KLA和英特尔公司担任过越来越多责任级别的职位，任职时间长达二十多年。Mobeck先生拥有圣克拉拉大学Leavey Biness学院的MBA和金融学士学位。
Kenneth S. Mobeck was appointed as the Company's Chief Financial Officer in January 2024. Prior to that position, he held the position of Chief Financial Officer of EDAP's U.S. subsidiary since joining the company in December 2022. Mr. Mobeck is a seasoned corporate and operational finance executive with extensive experience in MedTech and technology organizations leading finance and administrative functions. Prior to joining EDAP, Mr. Mobeck served as Vice President of Finance and Investor Relations at medical device manufacturer Accuray Inc., a leading global radiation therapy company. During his tenure, he was responsible for driving several key initiatives tied to improving the company's operating performance and strategic growth objectives. Before Accuray, he spent over two decades in positions with increasing levels of responsibility at Lumentum, Silicon Graphics, Hewlett Packard, KLA, and Intel Corporation. Mr. Mobeck holds an MBA and a BSC in Finance from the Leavey School of Business at Santa Clara University.- Kenneth Mobeck于2024年1月被任命为公司首席财务官。在担任该职位之前，他自2022年12月加入公司以来一直担任EDAP美国子公司的首席财务官一职。Mobeck先生是一位经验丰富的企业和运营财务主管，在医疗技术和领导财务和行政职能的技术组织方面拥有丰富的经验。在加入EDAP之前，Mobeck先生曾在全球领先的放射治疗公司医疗设备制造商Accuray Inc.担任财务和投资者关系副总裁。在任职期间，他负责推动与改善公司经营业绩和战略增长目标相关的几项关键举措。在加入Accuray之前，他曾在Lumentum、Silicon Graphics、惠普企业、KLA和英特尔公司担任过越来越多责任级别的职位，任职时间长达二十多年。Mobeck先生拥有圣克拉拉大学Leavey Biness学院的MBA和金融学士学位。
- Kenneth S. Mobeck was appointed as the Company's Chief Financial Officer in January 2024. Prior to that position, he held the position of Chief Financial Officer of EDAP's U.S. subsidiary since joining the company in December 2022. Mr. Mobeck is a seasoned corporate and operational finance executive with extensive experience in MedTech and technology organizations leading finance and administrative functions. Prior to joining EDAP, Mr. Mobeck served as Vice President of Finance and Investor Relations at medical device manufacturer Accuray Inc., a leading global radiation therapy company. During his tenure, he was responsible for driving several key initiatives tied to improving the company's operating performance and strategic growth objectives. Before Accuray, he spent over two decades in positions with increasing levels of responsibility at Lumentum, Silicon Graphics, Hewlett Packard, KLA, and Intel Corporation. Mr. Mobeck holds an MBA and a BSC in Finance from the Leavey School of Business at Santa Clara University.
- Sanket Shah
Sanket Shah于2025年9月被任命为公司总法律顾问和公司秘书。Shah先生带来了超过15年的法律和BINIS领导经验，支持高增长公司，包括医疗器械行业的公司。在加入EDAP之前，Shah先生曾在Paragon 28, Inc.担任副总法律顾问和助理公司秘书，该公司是一家专门提供足踝骨科解决方案的医疗器械公司。早些时候，沙阿在MRI引导放射治疗系统的领先供应商ViewRay工作了f年，在那里他被任命为总法律顾问和公司秘书。在加入ViewRay之前，Shah先生曾在受到高度监管的行业担任法律顾问，负责就涉及医疗设备和全球运营的复杂商业、合规和监管事项提供咨询。Shah先生拥有俄亥俄州立大学Biness Administration的学士学位和伊利诺伊大学芝加哥法学院的法学博士学位。
Sanket Shah was appointed as the Company's General Counsel and Corporate Secretary in September 2025.Prior to joining EDAP, Mr. Shah served as Deputy General Counsel and Assistant Corporate Secretary at Paragon 28, Inc., a medical device company that specialized exclusively in foot and ankle orthopedic solutions. Earlier, Mr. Shah spent four years at ViewRay, a leading provider of MRI guided radiation therapy systems, where he was appointed as General Counsel and Corporate Secretary. Before joining ViewRay, Mr. Shah served as counsel in highly regulated industries where he advised on complex commercial, compliance, and regulatory matters involving medical devices and global operations. Mr. Shah holds a B.S. in Business Administration from the Ohio State University and a J.D. from the University of Illinois Chicago School of Law.- Sanket Shah于2025年9月被任命为公司总法律顾问和公司秘书。Shah先生带来了超过15年的法律和BINIS领导经验，支持高增长公司，包括医疗器械行业的公司。在加入EDAP之前，Shah先生曾在Paragon 28, Inc.担任副总法律顾问和助理公司秘书，该公司是一家专门提供足踝骨科解决方案的医疗器械公司。早些时候，沙阿在MRI引导放射治疗系统的领先供应商ViewRay工作了f年，在那里他被任命为总法律顾问和公司秘书。在加入ViewRay之前，Shah先生曾在受到高度监管的行业担任法律顾问，负责就涉及医疗设备和全球运营的复杂商业、合规和监管事项提供咨询。Shah先生拥有俄亥俄州立大学Biness Administration的学士学位和伊利诺伊大学芝加哥法学院的法学博士学位。
- Sanket Shah was appointed as the Company's General Counsel and Corporate Secretary in September 2025.Prior to joining EDAP, Mr. Shah served as Deputy General Counsel and Assistant Corporate Secretary at Paragon 28, Inc., a medical device company that specialized exclusively in foot and ankle orthopedic solutions. Earlier, Mr. Shah spent four years at ViewRay, a leading provider of MRI guided radiation therapy systems, where he was appointed as General Counsel and Corporate Secretary. Before joining ViewRay, Mr. Shah served as counsel in highly regulated industries where he advised on complex commercial, compliance, and regulatory matters involving medical devices and global operations. Mr. Shah holds a B.S. in Business Administration from the Ohio State University and a J.D. from the University of Illinois Chicago School of Law.